Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 242

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data

Open access
Ott, Patrick A., Hodi, F. Stephen, Buchbinder, Elizabeth I. · 2015 · Frontiers in Oncology

Abstract

The role of angiogenesis as a mediator of immune regulation in the tumor microenvironment has recently come into focus. Furthermore, emerging evidence indicates that immunotherapy can lead to immune-mediated vasculopathy in the tumor, suggesting that the tumor vasculature may be an important interface between the tumor-directed immune response and the cancer itself. The advent of immune checkpoint inhibition as an effective immunotherapeutic strategy for many cancers has led to a better understanding of this interface. TheWhile, the inhibition of angiogenesis through the targeting of VEGF has been used successfully for the treatment of cancer for many years,. Angiogenesis is a complex process and the anti-tumor activity of VEGF-directed therapy has been explained by several potential mechanisms including 1) direct effect on cancer cells, 2) alteration of vascular function and tumor blood flow, and 3) inhibition of vasculature growth in the tumor. Mechanisms the mechanisms behind its successexplaining much of the success of anti-VEGF therapy in patients remains of its anti-tumor activity remain poorly understood, with stabilization of the vasculature with improved chemotherapy drug delivery being highlightedan emphasis on combination therapies in many malignancies. Initial studies of More recently, with the advent of immune checkpoint inhibition as an effective immunotherapeutic strategy for many cancers, the role of angiogenesis as a mediator of immune regulation in the tumor microenvironment has come into focus. Furthermore, emerging evidence indicates that immunotherapy can lead to immune-mediated vasculopathy in the tumor, suggesting that the tumor vasculature may be an important interface between the tumor-directed immune response and the cancer itself.Ttheis complex relationship between angiogenesis, VEGF signaling and the immune system suggest that the combination of immune checkpoint blockade with angiogenesis inhibition has potential. While the majority of this work has been performed in metastatic melanoma, immunotherapy is rapidly showing promise in a broad range of malignancies and efforts to enhance immunotherapy will broadly impact the future of oncology. Here we review the preclinical rationale and initial clinical investigations of combined angiogenesis inhibition and immunotherapy/immune checkpoint inhibition as a potentially promising combinatorial approach for cancer treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fonc.2015.00202

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 242

Metadata

Authors
Ott, P. A., Hodi, F. S., & Buchbinder, E. I.
Venue
Frontiers in Oncology
Published
2015-09-22
Volume
5
Pages
202-202
ISSN
2234-943X (ISSN-L)
OpenAlex
W2179115666
Cited by
242
References
14
FWCI
8.84
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data. https://app.cochat.ai/papers/10.3389/fonc.2015.00202
The paper
Ott, P. A., Hodi, F. S., & Buchbinder, E. I. (2015). Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data. Frontiers in Oncology. https://doi.org/10.3389/fonc.2015.00202

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.